Nautilus Biotechnology (NAUT) Projected to Announce Quarterly Earnings on Tuesday

Nautilus Biotechnology (NASDAQ:NAUT) is anticipated to post its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect the company to post earnings of ($0.1350) per share and revenue of $0.25 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, July 28, 2026 at 8:30 AM ET.

Nautilus Biotechnology (NASDAQ:NAUT) last announced its earnings results on Tuesday, April 28th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.02.

Nautilus Biotechnology Stock Down 2.9%

NAUT opened at $1.69 on Tuesday. The firm has a market capitalization of $214.77 million, a P/E ratio of -3.67 and a beta of 0.80. The stock’s 50 day moving average price is $2.23 and its two-hundred day moving average price is $2.46. Nautilus Biotechnology has a 12-month low of $0.62 and a 12-month high of $4.31.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Nautilus Biotechnology in a research report on Friday. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Nautilus Biotechnology has an average rating of “Hold” and a consensus price target of $4.00.

Insider Buying and Selling at Nautilus Biotechnology

In related news, major shareholder Ah Equity Partners Bio Ii, L.L sold 5,000,000 shares of the company’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $2.35, for a total value of $11,750,000.00. Following the completion of the transaction, the insider directly owned 971,885 shares in the company, valued at approximately $2,283,929.75. This represents a 83.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 41.10% of the company’s stock.

Hedge Funds Weigh In On Nautilus Biotechnology

Hedge funds have recently modified their holdings of the stock. Corient Private Wealth LLC lifted its holdings in Nautilus Biotechnology by 860.0% during the 2nd quarter. Corient Private Wealth LLC now owns 435,350 shares of the company’s stock valued at $316,000 after purchasing an additional 390,000 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Nautilus Biotechnology in the first quarter valued at approximately $194,000. Jane Street Group LLC boosted its holdings in shares of Nautilus Biotechnology by 304.1% in the 2nd quarter. Jane Street Group LLC now owns 290,369 shares of the company’s stock worth $210,000 after acquiring an additional 218,512 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Nautilus Biotechnology by 152.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 297,437 shares of the company’s stock worth $580,000 after acquiring an additional 179,721 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in Nautilus Biotechnology during the 4th quarter valued at $228,000. 50.71% of the stock is owned by institutional investors and hedge funds.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.